Verification of Kumamoto Declaration 2013 and Glycemic Targets for Elderly Patients with Diabetes in Japan for prevention of diabetic complications: A retrospective longitudinal study using outpatient clinical data

Shuhei Nakanishi1*, Hidenori Hirukawa1, Masashi Shimoda1, Fuminori Tatsumi1, Kenji Kohara1, Atsushi Obata1, Tomohiko Kimura1, Seizo Okauchi1, Tomoe Kinoshita1, Junpei Sanada1, Yoshiro Fushimi1, Momoyo Nishioka1, Akiko Mizoguchi1, Tomoatsu Mune1, Kohei Kaku2, Hidao Kaneto1

1Division of Diabetes, Metabolism and Endocrinology, and 2Department of General Internal Medicine 1, Kawasaki Hospital, Kawasaki Medical School, Okayama, Japan

Keywords
Japanese type 2 diabetes, JDS/JGS guideline, Kumamoto Declaration

*Correspondence
Shuhei Nakanishi
Tel: +81-86-462-1111
Fax: +81-86-464-1046
E-mail address: n-shuhei@umin.net

J Diabetes Investig 2019; 10: 290–301
doi: 10.1111/jdi.12909

ABSTRACT
Aims/Introduction: The present study examined the association between the onset of micro- and macroangiopathy in type 2 diabetes mellitus patients and levels of glycated hemoglobin (HbA1c) described in the Evidence-based Practice Guideline for the Treatment for Diabetes in Japan 2013 or those indicated in the Japan Diabetes Society and the Japan Geriatrics Society Joint Committee on Improving Care for Elderly Patients with Diabetes.

Materials and Methods: Patients with type 2 diabetes mellitus who visited the outpatient clinic at Kawasaki Medical School Hospital between 2000 and 2016 and received follow up for >2 years were eligible for the present study. Two datasets, comprising 2,424 or 3,316 patients without micro- or macroangiopathy at the start of follow up, were used, respectively. The Cox model was used in two categories of patients, younger and elderly, with the dividing line set at the age of 65 years.

Results: For the prevention of microangiopathy, in all patients, there was found to be no advantage in controlling HbA1c at a level of <6.0% based on the categories in the Evidence-based Practice Guideline for the Treatment for Diabetes in Japan 2013, and there was found to be a disadvantage in maintaining HbA1c ≥8.5% based on the categories in the Japan Diabetes Society and the Japan Geriatrics Society Joint Committee on Improving Care for Elderly Patients with Diabetes guideline. For the prevention of macroangiopathy in younger patients, there seemed to be an advantage in maintaining HbA1c within the range of 6.0–6.9% and <7.0% based on the Evidence-based Practice Guideline for the Treatment for Diabetes in Japan 2013 and the Japan Diabetes Society and the Japan Geriatrics Society Joint Committee on Improving Care for Elderly Patients with Diabetes, respectively.

Conclusions: In all type 2 diabetes mellitus patients, average HbA1c should be maintained <7.0% to prevent microangiopathy. However, in elderly patients, no optimal target for preventing macroangiopathy was found, in contrast to the younger patients in the present study.
INTRODUCTION
The ultimate goal for individuals with diabetes is to secure years of healthy life and to maintain the quality of life, just as in the case of healthy individuals. To achieve this objective, it is important to prevent the onset and progression of various diabetic complications. This new philosophy was initially described in the Japanese language Evidence-based Practice Guideline for the Treatment for Diabetes in Japan 2013, which was widely announced at the 56th annual meeting of the Japan Diabetes Society, held in Kumamoto, Japan, in 2013, and therefore became known as the "Kumamoto Declaration 2013". The declaration set the glycated hemoglobin (HbA1c) target level at <7.0% to ensure the prevention of diabetic microvascular complications, while recommending that glycemic control goals be determined individually. In daily clinical practice, in addition to the HbA1c level of 7%, HbA1c of 6 and 8% should also be considered as measures of glycemic control. HbA1c of 6% represents the optimal target for ensuring normalization of glucose levels, in an ideal scenario. Indeed, a recent large clinical trial carried out in Japan (Japan Diabetes Optimal Integrated Treatment study for three major risk factors of cardiovascular diseases [J-DOIT3]) showed that strict control of blood glucose levels by maintaining average HbA1c at 6.8% and of several other risk factors prevented micro- and macroangiopathy even when compared with a slightly higher HbA1c of 7.2%.

In contrast, the Japan Diabetes Society (JDS)/Japan Geriatrics Society (JGS) Joint Committee on Improving Care for Elderly Patients with Diabetes was launched in April 2015 (JDS/JGS). This report recommended that glycemicy targets for elderly patients be determined for each patient based on consideration of the patient's age, medication(s) used, cognitive function, basic/instrumental activities of daily living and comorbidities/functional impairments. The HbA1c goals in this report were <7.0% with intact cognitive function and no impairment of activities of daily living, and <8.5% with moderate or severe dementia, impairment(s) of basic activities of daily living, or the presence of multiple comorbidities or functional impairments.

Although these guidelines are useful and have broad utility, two clinical questions arise with respect to the risk of diabetic complications. One question is the risks inherent in strict control of HbA1c at <6.0% in elderly patients. The other is the risks in controlling HbA1c at a level of >8.5% in younger patients. In the present study, we examined the association between target levels of HbA1c described in the Kumamoto Declaration or in the JDS/JGS and the onset of micro- and macroangiopathy in younger and elderly Japanese patients – with the dividing line set at the age of 65 years – who had type 2 diabetes.

MATERIALS AND METHODS
Study population and patient preparation
Patients who visited the diabetes outpatient clinic at Kawasaki Medical School Hospital between 2000 and 2016, and were diagnosed with type 2 diabetes and who could be followed for a period of >2 years were eligible for the present study. To investigate the onset of micro- and macroangiopathy, two datasets were prepared. One comprised 2,424 patients without macroangiopathy at the start of follow-up with no consideration paid to macroangiopathy. The other dataset totaled 3,316 patients without macroangiopathy at the start of follow-up with no consideration paid to macroangiopathy. In the dataset comprising 2,424 patients with macroangiopathy, 1,006 patients were followed for >2 years and <3 years from whom two sets of HbA1c data during the 3 months from August to October every year were obtained, with the aim of reducing the effects of seasonal variation. In addition, 306, 203, 165, 157, 162, 101, 53, 62, 57, 56, 56, 11, 15 and 14 patients were followed for 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 years, respectively, from whom HbA1c data based on the number of years they were followed were obtained. In the dataset comprising 3,316 patients for macroangiopathy, 1,166 patients were followed for >2 years and <3 years from whom two sets of HbA1c data were obtained. Furthermore, 470, 288, 235, 256, 149, 81, 103, 87, 86, 101, 15, 21 and 18 patients were followed for 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 years, respectively, from whom HbA1c data based on the number of years they were followed were obtained. To evaluate the status of prolonged glycemic control, average HbA1c was calculated in every patient for the number of observation years. The hospital’s ethics committee approved the study protocol, and information on the study was provided to the public by the Internet, instead of informed consent being obtained from each patient (No. 2847). Data collection for variables, such as type(s) of medication and duration of diabetes, as well as biochemical data, was carried out starting with the first visit for the 3 months from August to October of every year, with the aim of reducing the effect of seasonal variation in HbA1c level described previously.

We divided the patients by the average HbA1c value for each year during the observation period into four groups based on the Kumamoto Declaration, as follows: group K1, HbA1c <6%; group K2, 6% ≤ HbA1c <7%; group K3, 7% ≤ HbA1c < 8%; and group K4, HbA1c ≥8%. In addition, we divided the patients by average HbA1c value into four groups with modifications based on the JDS/JGS, as follows: group E1, HbA1c <7%; group E2, 7% ≤ HbA1c <8%; group E3, 8% ≤ HbA1c < 8.5%; and group E4, HbA1c ≥8.5%. Furthermore, to investigate the appropriateness of these cut-off values for younger and elderly patients, patients were divided into two categories by age at the start of the follow-up period: younger (aged <65 years) and elderly patients (aged ≥65 years).

We compared the frequency of onset of micro- or macroangiopathy among the aforementioned four groups in the younger and elderly patients using the two individualized datasets. In all patients, macroangiopathy was assessed as follows: the diagnosis of the occurrence of ischemic heart disease events was made by cardiologists based on clinical symptoms...
Onset of microangiopathy in four glycemic control groups based on the two guidelines in patients without diabetic microangiopathy at baseline

The mean age and follow-up period were 53.1 ± 9.9 years and 4.55 ± 3.63 years, respectively, in younger patients (aged <65 years) at the start of this study. The mean age and follow-up period were 72.2 ± 5.2 years and 4.05 ± 3.43 years, respectively, in elderly patients (aged ≥65 years) at the start of the study. The numbers of younger and elderly patients in each group classified in accordance with the average HbA1c value based on the Kumamoto Declaration were as follows: 137 and 107 in group K1, 760 and 566 in group K2, 340 and 279 in group K3, and 167 and 68 in group K4, respectively. Table 1 shows the clinical characteristics at baseline. The numbers of younger and elderly patients in each group classified by average HbA1c value based on the JDS/JGS guidelines were as follows: 897 and 673 in group E1, 340 and 279 in group E2, 66 and 37 in group E3, and 101 and 31 in group E4, respectively. Table 2 shows the clinical characteristics at baseline.

The Cox proportional hazards model was used in analysis of the four categories based on the Kumamoto Declaration, with the crude hazard ratios of K1, K3 and K4 in younger patients, compared with the reference group K2. The crude hazard ratios of K1, K3 and K4 were 1.07 (95% confidence interval [CI] 0.69–1.67, \( P = 0.76 \)), 1.37 (95% CI 1.09–1.72, \( P = 0.006 \)) and 1.89 (95% CI 1.45–2.48, \( P < 0.0001 \)), respectively. In elderly patients, the crude hazard ratios of K1, K3 and K4, compared with the reference group K2, were 0.78 (95% CI 0.51–1.20, \( P = 0.26 \)), 1.31 (95% CI 1.04–1.66, \( P = 0.023 \)) and 1.57 (95% CI 1.10–2.25, \( P = 0.013 \)), respectively. After adjustment was carried out for age, sex, duration of diabetes, medication(s) used for hypertension or dyslipidemia and BMI at the start of the study, the hazard ratios of K1, K3 and K4, compared with the reference group K2, were 1.02 (95% CI 0.62–1.66, \( P = 0.95 \)), 1.35 (95% CI 1.06–1.72, \( P = 0.014 \)) and 1.94 (95% CI 1.43–2.64, \( P < 0.0001 \)), respectively (Figure 1a).

In elderly patients, the hazard ratios of K1, K3 and K4, compared with the reference group K2, were 0.82 (95% CI 0.52–1.29, \( P = 0.39 \)), 1.27 (95% CI 0.98–1.64, \( P = 0.069 \)) and 1.46 (95% CI 0.99–2.15, \( P = 0.057 \)), respectively (Figure 1b). These results were comparable with the results of the rate for person-years.

The Cox proportional hazards model was used in analysis of the four categories based on the JDS/JGS guidelines, with the crude hazard ratios of E2, E3 and E4 in younger patients, compared with the reference group E1. The crude hazard ratios of E2, E3 and E4 were 1.36 (95% CI 1.09–1.70, \( P = 0.006 \)), 1.90 (95% CI 1.30–2.76, \( P = 0.0009 \)) and 1.87 (95% CI 1.35–2.58, \( P = 0.0002 \)), respectively. In elderly patients, the crude hazard ratios of E2, E3 and E4, compared with the reference group E1, were 1.36 (95% CI 1.09–1.71, \( P = 0.008 \)), 1.55 (95% CI 1.00–2.40, \( P = 0.051 \)) and 1.78 (95% CI 1.03–3.08, \( P = 0.037 \)).
Table 1 | Baseline clinical characteristics in each group based on the Kumamoto Declaration among younger patients and elderly patients without microangiopathy at baseline

| Younger patients | <6.0% | 6.0–<7.0% | 7.0–<8.0% | ≥8.0% |
|------------------|-------|-----------|-----------|-------|
| M/F (n)          | 104/33| 461/299   | 204/136   | 98/69 |
| Development of microangiopathy | 22 (8/2/13) | 176 (124/26/66) | 137 (69/37/87) | 79 (45/26/60) |
| during follow-up period (neuro/retino/nephro) | | | | |
| Age (years)      | 52.7 ± 10.7 | 54.5 ± 8.8 | 53.5 ± 9.6 | 46.6 ± 11.7* |
| Rates/1,000 person-years | 48.6 | 52.6 | 75.3 | 102.3 |
| Duration of type 2 diabetes (years) | 3.7 ± 4.7 | 5.1 ± 6.5 | 6.8 ± 6.6* | 6.8 ± 6.9* |
| BMI (kg/m²)      | 25.6 ± 4.7 | 25.3 ± 4.6 | 25.1 ± 4.5 | 27.1 ± 5.3* |
| Mean HbA1c (%)   | 5.7 ± 0.4z | 6.5 ± 0.6 | 7.4 ± 0.9* | 8.8 ± 1.7* |
| SBP (mmHg)       | 126 ± 16   | 126 ± 16   | 126 ± 16   | 126 ± 17   |
| DBP (mmHg)       | 74 ± 11    | 74 ± 11    | 74 ± 12    | 74 ± 13    |
| TCH (mg/dL)      | 189 ± 34   | 192 ± 34   | 198 ± 36   | 209 ± 54*  |
| HDLC (mg/dL)     | 52 ± 14    | 53 ± 14    | 51 ± 14    | 48 ± 16*   |
| TG (mg/dL)       | 141 ± 71   | 159 ± 146  | 175 ± 129  | 254 ± 385* |
| Treatment for diabetes (n) | | | | |
| Insulin/SU/glucosidase inhibitors/TZD | 3/5/3/17 | 17/76/86/106 | 32/64/46/44 | 46/33/8/20 |
| BG/α-G/DPPI | 19/9/16 | 152/84/78 | 78/48/26 | 55/20/19 |
| SGLT2i/GLP-1RA | 0/0 | 0/3 | 0/3 | 0/1 |
| Treatment for dyslipidemia (n) | 60 | 327 | 122 | 43 |
| Treatment for hypertension (n) | 48 | 292 | 106 | 33 |

| Elderly patients | <6.0% | 6.0–<7.0% | 7.0–<8.0% | ≥8.0% |
|------------------|-------|-----------|-----------|-------|
| M/F (n)          | 66/41| 339/227   | 164/115   | 35/33 |
| Development of microangiopathy during follow-up period (neuro/retino/nephro) | 25 (11/1/16) | 166 (79/28/109) | 126 (72/50/74) | 37 (29/17/19) |
| Age (years)      | 72.0 ± 4.9 | 71.7 ± 5.0 | 73.0 ± 5.6 | 73.9 ± 5.3* |
| Rates/1,000 person-years | 63.8 | 73.3 | 106.9 | 125.0 |
| Duration of type 2 diabetes (years) | 68 ± 8.4 | 67 ± 7.6 | 95 ± 8.6* | 113 ± 10.8* |
| BMI (kg/m²)      | 23.1 ± 3.3 | 23.6 ± 3.5 | 23.2 ± 3.5 | 23.7 ± 4.3 |
| Mean HbA1c (%)   | 5.8 ± 0.4* | 6.5 ± 0.5 | 7.4 ± 0.8* | 9.0 ± 1.6* |
| SBP (mmHg)       | 125 ± 15   | 127 ± 16   | 127 ± 16   | 133 ± 19   |
| DBP (mmHg)       | 69 ± 10    | 70 ± 10    | 70 ± 10    | 73 ± 10    |
| TCH (mg/dL)      | 185 ± 33   | 198 ± 84   | 192 ± 37   | 192 ± 41   |
| HDLC (mg/dL)     | 57 ± 18    | 54 ± 17    | 52 ± 14    | 50 ± 14    |
| TG (mg/dL)       | 127 ± 72   | 139 ± 76   | 143 ± 76   | 156 ± 89   |
| Treatment for diabetes (n) | | | | |
| Insulin/SU/glucosidase inhibitors/TZD | 1/7/11/10 | 14/78/70/62 | 27/80/37/24 | 16/18/7/0 |
| BG/α-G/DPPI          | 9/14/9 | 62/68/57 | 38/40/19 | 7/10/1 |
| SGLT2i/GLP-1RA | 0/0 | 0/0 | 1/0 | 0/0 |
| Treatment for dyslipidemia (n) | 39 | 341 | 83 | 16 |
| Treatment for hypertension (n) | 61 | 275 | 116 | 15 |

Data are shown as mean ± standard deviation. *P < 0.05 compared with the category of “6.0–7.0%” after adjustment for age and sex. α-Gl, α-glucosidase inhibitors; BG, biguanide; BMI, body mass index; DBP, diastolic blood pressure; DPPI, dipeptidyl peptidase-4 inhibitors; F, female;GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated hemoglobin; HDLC, high-density lipoprotein cholesterol; M, male; nephro, nephropathy; neuro, neuropathy; retinopathy; SBP, systolic blood pressure; SGLT2i, sodium–glucose co-transporter 2 inhibitors; SU, sulfonylureas; TCH, total cholesterol; TG, triglycerides; TZD, thiazolidinedione.

respectively. After adjustment for the same factors as those described above, the hazard ratios of E2, E3 and E4 in younger patients, compared with the reference group E1, were 1.35 (95% CI 1.07–1.71, P = 0.013), 1.96 (95% CI 1.29–2.97, P = 0.0017) and 1.93 (95% CI 1.35–2.77, P = 0.0004), respectively (Figure 2a). In elderly patients, the hazard ratios of E2, E3 and E4, compared with the reference group E1, were 1.30 (95% CI 1.01–1.68, P = 0.039), 1.36 (95% CI 0.85–2.17,
Table 2 | Baseline clinical characteristics in each group based on the Japan Diabetes Society/Japan Geriatrics Society among younger patients and elderly patients without microangiopathy at baseline

| Younger patients | <7.0% | 7.0–<8.0% | 8.0–<8.5% | ≥8.5% |
|------------------|-------|------------|-----------|-------|
| M/F (n)          | 565/332 | 204/136 | 39/27 | 59/42 |
| Development of microangiopathy during follow-up period (neuro/retino/nephro) | 198 (74/28/137) | 137 (69/37/87) | 33 (17/11/27) | 46 (28/15/33) |
| Age (years)      | 54.2 ± 9.2 | 53.5 ± 9.6 | 48.4 ± 12.5* | 45.5 ± 11.2* |
| Rates/1,000 person-years | 52.1 | 75.3 | 105.4 | 100.2 |
| Duration of type 2 diabetes (years) | 4.9 ± 6.3 | 6.8 ± 6.6 | 6.9 ± 6.4 | 6.8 ± 7.2 |
| BMI (kg/m²)      | 25.3 ± 4.6 | 25.1 ± 4.5 | 26.9 ± 5.2* | 27.3 ± 5.3* |
| Mean HbA1c (%)   | 64 ± 0.6 | 7.4 ± 0.9* | 8.2 ± 1.6* | 9.2 ± 1.7* |
| SBP (mmHg)       | 126 ± 16 | 126 ± 16 | 127 ± 18 | 125 ± 16 |
| DBP (mmHg)       | 74 ± 11 | 74 ± 12 | 77 ± 11 | 72 ± 14 |
| TCH (mg/dL)      | 192 ± 34 | 198 ± 36 | 202 ± 35 | 214 ± 62* |
| HDLC (mg/dL)     | 53 ± 14 | 51 ± 14 | 49 ± 10 | 48 ± 18* |
| TG (mg/dL)       | 157 ± 137 | 175 ± 129 | 195 ± 125 | 291 ± 477* |
| Treatment for diabetes (n) | 20/81/89/123 | 32/64/46/44 | 18/13/5/8 | 28/20/3/0 |
| Treatment for dyslipidemia (n) | 405/268 | 164/115 | 21/16 | 14/17 |
| Treatment for hypertension (n) | 387 | 122 | 14 | 29 |

| Elderly patients | <7.0% | 7.0–<8.0% | 8.0–<8.5% | ≥8.5% |
|------------------|-------|------------|-----------|-------|
| M/F (n)          | 405/268 | 164/115 | 21/16 | 14/17 |
| Development of microangiopathy during follow-up period (neuro/retino/nephro) | 191 (90/29/125) | 126 (72/50/74) | 23 (20/9/9) | 14 (9/8/10) |
| Age (years)      | 71.8 ± 5.0 | 73.0 ± 5.6* | 74.0 ± 5.8 | 73.7 ± 4.7 |
| Rates/1,000 person-years | 71.9 | 106.9 | 127.8 | 120.7 |
| Duration of type 2 diabetes (years) | 6.7 ± 7.7 | 95 ± 8.6* | 124 ± 12.1* | 97 ± 8.8 |
| BMI (kg/m²)      | 23.5 ± 3.5 | 23.2 ± 3.5 | 242 ± 3.9 | 22.9 ± 4.6 |
| Mean HbA1c (%)   | 64 ± 0.6 | 74 ± 0.8* | 85 ± 1.6* | 96 ± 1.4* |
| SBP (mmHg)       | 127 ± 15 | 127 ± 16 | 128 ± 17 | 139 ± 21* |
| DBP (mmHg)       | 70 ± 10 | 70 ± 10 | 72 ± 11 | 75 ± 10 |
| TCH (mg/dL)      | 196 ± 78 | 192 ± 37 | 192 ± 35 | 192 ± 47 |
| HDLC (mg/dL)     | 55 ± 17 | 52 ± 14 | 50 ± 15 | 51 ± 13 |
| TG (mg/dL)       | 137 ± 75 | 143 ± 76 | 158 ± 86 | 154 ± 94 |
| Treatment for diabetes (n) | 15/85/81/72 | 27/80/37/24 | 6/10/4/0 | 10/8/3/0 |
| Treatment for dyslipidemia (n) | 71/82/66 | 38/40/19 | 4/7/0 | 55/3/1 |
| Treatment for hypertension (n) | 0/0 | 0/0 | 0/0 | 0/0 |

Data are shown as mean ± standard deviation. *P < 0.05 compared with the category of <7.0% after adjustment for age and sex. α-Gl, alpha-glucosidase inhibitors; BG, biguanide; BMI, body mass index; DBP, diastolic blood pressure; DPP4I, dipeptidyl peptidase-4 inhibitors; F, female; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated hemoglobin; HDLC, high-density lipoprotein cholesterol; M, male; nephro, nephropathy; neuro, neuropathy; retino, retinopathy; SBP, systolic blood pressure; SGLT2I, sodium–glucose co-transporter 2 inhibitors; SU, sulfonylureas; TCH, total cholesterol; TG, triglycerides; TZD, thiazolidinedione.

P = 0.20) and 1.79 (95% CI 1.00–3.19, P = 0.049), respectively (Figure 2b). These results were comparable with the results of the rate from person-years.

In addition, the adjusted hazard ratio for average HbA1c (%) was 1.26 (95% CI 1.14–1.40, P < 0.0001) in younger patients and 1.22 (95% CI 1.06–1.41, P = 0.007) in elderly patients, which
Figure 1 | Adjusted hazard ratios for microangiopathy in (a) younger and (b) elderly patients. The patients were divided into four groups by average glycated hemoglobin (HbA1c) value during the observation period based on the Kumamoto Declaration. Group K1, HbA1c <6%; group K2, 6% ≤ HbA1c < 7%; group K3, 7% ≤ HbA1c < 8%; and group K4, HbA1c ≥8%. *P < 0.05 compared with group K2. †P < 0.01 compared with group K2.

Figure 2 | Adjusted hazard ratios for microangiopathy in (a) younger and (b) elderly patients. The patients were divided into four groups by average glycated hemoglobin (HbA1c) value during the observation period based on the Japan Diabetes Society/Japan Geriatrics Society guidelines. Group E1, HbA1c <7%; group E2, 7% ≤ HbA1c < 8%; group E3, 8% ≤ HbA1c < 8.5%; and group E4, HbA1c ≥8.5%. *P < 0.05 compared with group E1. †P < 0.01 compared with group E1.
indicated the benefit of strict glycemic control for the prevention of microangiopathy in all patients in the present study.

**Onset of macroangiopathy in four glycemic control groups based on the two guidelines in patients without diabetic macroangiopathy at baseline**

The mean age and follow-up period were 53.5 ± 9.6 years and 4.83 ± 3.64 years, respectively, in younger patients (aged <65 years). The mean age and follow-up period were 72.5 ± 5.3 years and 4.63 ± 3.50 years, respectively, in elderly patients (aged ≥65 years). The numbers of younger and elderly patients in each group divided by the average HbA1c value based on the Kumamoto Declaration were as follows: 157 and 122 in group K1, 942 and 687 in group K2, 547 and 444 in group K3, and 281 and 136 in group K4, respectively. Table 3 shows the clinical characteristics at baseline. The numbers of younger and elderly patients in each group divided by the average HbA1c value based on the JDS/JGS guidelines were as follows: 1,099 and 809 in group E1, 547 and 444 in group E2, 107 and 71 in group E3, and 134 and 65 in group E4, in younger and elderly patients, respectively. Table 4 shows the clinical characteristics at baseline.

The Cox proportional hazards model was used in analysis of the four categories based on the Kumamoto Declaration, with the crude hazard ratios of K1, K3 and K4 in younger patients, compared with the reference group K2. The crude hazard ratios of K1, K3 and K4 were 0.77 (95% CI 0.39–1.52, \( P = 0.44 \)), 1.59 (95% CI 1.22–2.07, \( P = 0.0005 \)) and 1.36 (95% CI 0.97–1.91, \( P = 0.079 \)), respectively. In elderly patients, the crude hazard ratios of K1, K3 and K4, compared with the reference group K2, were 0.84 (95% CI 0.50–1.41, \( P = 0.51 \)), 0.95 (95% CI 0.74–1.22, \( P = 0.69 \)) and 0.96 (95% CI 0.66–1.41, \( P = 0.84 \)), respectively. After adjustment was carried out for the same factors described above, the hazard ratios of K1, K3 and K4 were 0.79 (95% CI 0.38–1.63, \( P = 0.52 \)), 1.69 (95% CI 1.27–2.24, \( P = 0.0003 \)) and 1.55 (95% CI 1.06–2.27, \( P = 0.0233 \)), respectively (Figure 3a). These results were comparable with the results of the rate from person-years. In elderly patients, the hazard ratios of E2, E3 and E4, compared with the reference group E1, were 1.72 (95% CI 1.30–2.27, \( P = 0.0001 \)), 1.63 (95% CI 1.00–2.65, \( P = 0.048 \)) and 1.54 (95% CI 0.96–2.48, \( P = 0.072 \)), respectively, in younger patients (Figure 4a).

In elderly patients, the hazard ratios of E2, E3 and E4, compared with the reference group E1, were 0.96 (95% CI 0.74–1.25, \( P = 0.78 \)), 0.80 (95% CI 0.46–1.40, \( P = 0.44 \)) and 1.27 (95% CI 0.75–2.15, \( P = 0.37 \)), respectively (Figure 4b). These results were comparable with the results of the rate from person-years.

The adjusted hazard ratio for average HbA1c (%) was 1.26 (95% CI 1.10–1.43, \( P = 0.0006 \)) in younger patients and 1.02 (95% CI 0.87–1.19, \( P = 0.83 \)) in elderly patients, which indicated a benefit in strict glycemic control for the prevention of macroangiopathy only in younger patients in the present study.

**DISCUSSION**

The present retrospective study validated the HbA1c categories as defined in the Kumamoto Declaration, indicating a disadvantage in blood glucose control of >7.0% in average HbA1c for younger patients for preventing micro- and macroangiopathy. At the same time, the study validated the HbA1c categories indicated in the Improving Care for Elderly Patients with Diabetes, showing an advantage and disadvantage in blood glucose control of <7.0% and >8.5% in average HbA1c, respectively, for elderly patients for preventing microangiopathy. These results showed the validity of the two guidelines for Japanese patients with type 2 diabetes.

For validation of the Kumamoto Declaration, HbA1c 6.0% was set as the optimal target for ensuring normalization of blood glucose levels, ideally based on appropriate diet/exercise therapy alone or with drug therapy, without causing adverse events, such as hypoglycemia. In addition, the target was set for relatively young individuals with a short duration of diabetes without a history of cardiovascular disease. This approach is reasonable, because only a small percentage of patients would receive benefits from an average HbA1c at <6.0% in comparison with HbA1c of 6.0–6.9%, given the present study's results regarding both micro- and macroangiopathy. In contrast, blood glucose control for average HbA1c of ≥7.0% had obvious disadvantages in terms of micro- and macroangiopathy among patients aged <65 years in the present study. Accordingly, maintaining HbA1c between 6.0 and 7.0% could be meaningful for patients aged <65 years. Indeed, in the American Diabetes Association consensus guideline, glycemic recommendations for many non-pregnant adults with diabetes are <7.0% HbA1c. On the contrary, however, for elderly patients, these benefits were less obvious in terms of preventing microangiopathy, whereas no benefit was observed in terms of preventing macroangiopathy, after adjustment was made for several factors. There are two possible reasons for this discrepancy of results between the two age categories. One is that the follow-up period was relatively short, and the other is that the participation number of elderly patients was small compared with that of younger patients.
Table 3 | Baseline clinical characteristics in each group based on the Kumamoto Declaration among younger patients and elderly patients without macroangiopathy at baseline

| Younger patients | <6.0% | 6.0–<7.0% | 7.0–<8.0% | ≥8.0% |
|------------------|-------|-----------|-----------|-------|
| M/F (n)          | 116/41| 571/371   | 328/219   | 155/126|
| Development of macroangiopathy during follow-up period (IHD/CVD) | 9 (4/5) | 105 (56/59) | 121 (63/68) | 48 (28/20) |
| Age (years)      | 52.9 ± 10.5 | 54.6 ± 8.8 | 54.0 ± 9.1 | 49.4 ± 11.2* |
| Rates/1,000 person-years | 170 | 24.2 | 40.1 | 33.6 |
| Duration of type 2 diabetes (years) | 4.9 ± 5.6 | 5.9 ± 6.6 | 8.8 ± 7.5* | 9.4 ± 7.8* |
| BMI (kg/m²)      | 25.5 ± 4.9 | 25.1 ± 4.6 | 25.0 ± 4.7 | 26.2 ± 5.1* |
| Mean HbA1c (%)   | 5.8 ± 0.4* | 6.6 ± 0.6 | 7.5 ± 1.1* | 8.9 ± 1.6* |
| SBP (mmHg)       | 125 ± 16 | 126 ± 16 | 127 ± 17 | 127 ± 18 |
| DBP (mmHg)       | 73 ± 12 | 74 ± 11 | 74 ± 12 | 74 ± 12 |
| TCH (mg/dL)      | 185 ± 34 | 189 ± 35 | 194 ± 35 | 204 ± 49* |
| HDLC (mg/dL)     | 52 ± 14 | 53 ± 15 | 51 ± 14 | 51 ± 16 |
| TG (mg/dL)       | 141 ± 73 | 156 ± 135 | 174 ± 182 | 221 ± 307* |
| Treatment for diabetes (n) | Insulin/SU/glinides/TZD | 7/4/6/18 | 47/99/105/139 | 85/109/66/69 | 96/49/12/33 |
|                  | BG/α-GI/DPP4I | 25/10/22 | 218/104/102 | 140/66/49 | 96/36/24 |
|                  | SGLT2/GLP-1RA | 0/1 | 1/8 | 0/7 | 0/3 |
| Treatment for dyslipidemia (n) | 73 | 389 | 180 | 88 |
| Treatment for hypertension (n) | 65 | 405 | 183 | 87 |

| Elderly patients | <6.0% | 6.0–<7.0% | 7.0–<8.0% | ≥8.0% |
|------------------|-------|-----------|-----------|-------|
| M/F (n)          | 68/54 | 404/283   | 243/201   | 66/70 |
| Development of macroangiopathy during follow-up period (IHD/CVD) | 16 (6/10) | 148 (73/93) | 110 (64/56) | 32 (26/8) |
| Age (years)      | 72.3 ± 4.8 | 72.1 ± 5.2 | 73.1 ± 5.4* | 72.9 ± 5.2 |
| Rates/1,000 person-years | 360 | 483 | 485 | 493 |
| Duration of type 2 diabetes (years) | 7.6 ± 9.1 | 8.8 ± 9.3 | 13.0 ± 9.7* | 139 ± 8.8* |
| BMI (kg/m²)      | 230 ± 3.3 | 235 ± 3.5 | 233 ± 3.6 | 234 ± 3.8 |
| Mean HbA1c (%)   | 5.8 ± 0.4* | 6.5 ± 0.6 | 7.4 ± 0.8* | 8.7 ± 1.4* |
| SBP (mmHg)       | 125 ± 15 | 127 ± 16 | 127 ± 16 | 131 ± 19 |
| DBP (mmHg)       | 68 ± 10 | 69 ± 10 | 69 ± 10 | 71 ± 11 |
| TCH (mg/dL)      | 183 ± 33 | 194 ± 78 | 192 ± 36 | 191 ± 40 |
| HDLC (mg/dL)     | 57 ± 17 | 54 ± 18 | 54 ± 16 | 53 ± 15 |
| TG (mg/dL)       | 129 ± 62 | 135 ± 73 | 137 ± 98 | 147 ± 96 |
| Treatment for diabetes (n) | Insulin/SU/glinides/TZD | 7/4/6/18 | 47/99/105/139 | 85/109/66/69 | 96/49/12/33 |
|                  | BG/α-GI/DPP4I | 25/10/22 | 218/104/102 | 140/66/49 | 96/36/24 |
|                  | SGLT2/GLP-1RA | 0/1 | 1/8 | 0/7 | 0/3 |
| Treatment for dyslipidemia (n) | 73 | 389 | 180 | 88 |
| Treatment for hypertension (n) | 65 | 405 | 183 | 87 |

Data are shown as mean ± standard deviation. *P < 0.05 compared with the category of 6.0–7.0%: after adjustment for age and sex. α-Gl, alpha-glucosidase inhibitor; BG, biguanide; BMI, body mass index; DBP, diastolic blood pressure; CVD, cerebral vascular disease; DPP4I, dipeptidyl peptidase-4 inhibitors; F, female; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated hemoglobin; HDLC, high-density lipoprotein cholesterol; IHD, ischemic heart disease; M, male; SBP, systolic blood pressure; SGLT2I, sodium–glucose co-transporter 2 inhibitors; SU, sulfonylureas; TCH, total cholesterol; TG, triglycerides; TZD, thiazolidinedione.

Using the JDS/JGS criteria, controlling the average HbA1c to <7.0% had benefits in terms of microangiopathy compared with the group with HbA1c of >8.5% in all patients. This result might indicate that blood glucose control of >8.5% had a disadvantage, even in elderly patients aged >65 years. Furthermore, compared with maintaining HbA1c at a level of <7.0%, an average HbA1c of ≥7.0% had significantly elevated risks in younger patients. In elderly patients, compared with
maintaining HbA1c at <7.0%, maintaining average HbA1c at between 7.0 and 8.0% had significantly elevated risks. These results show that the optimal target of average HbA1c in terms of preventing microangiopathy might be <7.0% for all patients, supporting the JDS/JGS consensus, which defines the lower and upper limits of the glycemic target to ensure safer glycemic control by accounting for patient background and health status, comorbidities, risk of severe hypoglycemia, and life expectancy3.

Table 4 | Baseline clinical characteristics in each group based on the Japan Diabetes Society/Japan Geriatrics Society among younger patients and elderly patients without macroangiopathy at baseline

|                          | <7.0% | 7.0–<8.0% | 8.0–<8.5% | ≥8.5% |
|--------------------------|-------|-----------|-----------|-------|
| M/F (n)                  | 687/412 | 328/219 | 59/48 | 96/78 |
| Development of macroangiopathy during follow-up period (IHD/CVD) | 114 | 121 | 21 | 27 |
| Age (years)              | 54.3 ± 9.1 | 54.0 ± 9.1 | 52.3 ± 11.3 | 47.7 ± 10.8* |
| Rates/1,000 person-years | 23.4 | 40.1 | 34.3 | 33.1 |
| Duration of type 2 diabetes (years) | 5.8 ± 6.5 | 8.8 ± 7.5* | 10.0 ± 7.5* | 9.0 ± 8.0* |
| BMI (kg/m²)              | 25.2 ± 4.7 | 25.0 ± 4.7 | 25.6 ± 4.7 | 26.7 ± 5.3* |
| Mean HbA1c (%)           | 6.5 ± 0.7 | 7.5 ± 1.1* | 8.3 ± 1.4* | 9.3 ± 1.6* |
| SBP (mmHg)               | 126 ± 16 | 127 ± 17 | 128 ± 18 | 126 ± 17 |
| DBP (mmHg)               | 74 ± 11 | 74 ± 12 | 75 ± 12 | 73 ± 12 |
| TCH (mg/dL)              | 189 ± 35 | 194 ± 35 | 201 ± 38* | 206 ± 54* |
| HDLC (mg/dL)             | 53 ± 14 | 51 ± 14 | 52 ± 13 | 50 ± 17 |
| TG (mg/dL)               | 154 ± 128 | 174 ± 182 | 186 ± 137 | 240 ± 370* |
| Treatment for diabetes (n) | 54/103/111/157 | 85/109/66/69 | 37/21/5/14 | 59/28/7/19 |
| Treatment for dyslipidemia (n) | 52/109 | 70/66 | 37/21 | 59/28 |
| Treatment for hypertension (n) | 52/109 | 70/66 | 37/21 | 59/28 |

|                          | <7.0% | 7.0–<8.0% | 8.0–<8.5% | ≥8.5% |
|--------------------------|-------|-----------|-----------|-------|
| M/F (n)                  | 472/337 | 243/201 | 37/34 | 29/36 |
| Development of macroangiopathy during follow-up period (IHD/CVD) | 164 | 110 | 15 | 17 |
| Age (years)              | 72.1 ± 5.1 | 73.1 ± 5.4* | 72.7 ± 5.2 | 73.1 ± 5.3 |
| Rates/1,000 person-years | 468 | 485 | 426 | 57.2 |
| Duration of type 2 diabetes (years) | 8.6 ± 9.3 | 13.0 ± 9.7* | 13.6 ± 8.5* | 14.3 ± 9.3* |
| BMI (kg/m²)              | 234 ± 3.5 | 233 ± 3.6 | 238 ± 3.8 | 230 ± 3.8 |
| Mean HbA1c (%)           | 64 ± 0.6 | 74 ± 0.8* | 83 ± 1.3* | 92 ± 1.2* |
| SBP (mmHg)               | 127 ± 16 | 127 ± 16 | 131 ± 17 | 132 ± 22 |
| DBP (mmHg)               | 69 ± 10 | 69 ± 10 | 72 ± 10 | 71 ± 11 |
| TCH (mg/dL)              | 192 ± 73 | 192 ± 36 | 190 ± 38 | 193 ± 43 |
| HDLC (mg/dL)             | 54 ± 18 | 54 ± 16 | 51 ± 15 | 54 ± 16 |
| TG (mg/dL)               | 134 ± 71 | 137 ± 98 | 148 ± 86 | 146 ± 108 |
| Treatment for diabetes (n) | 33/101/97/69 | 58/146/41/36 | 16/18/4/4 | 18/24/3/5 |
| Treatment for dyslipidemia (n) | 99/90/78 | 64/70/25 | 6/15/3 | 6/11/4 |
| Treatment for hypertension (n) | 21/3 | 18/25 | 18/25 | 18/25 |

Data are shown as mean ± standard deviation. *P < 0.05 compared with the category of "<7.0%" after adjustment for age and sex. α-Gl, alpha-glucosidase inhibitors; BG, biguanide; BMI, body mass index; DBP, diastolic blood pressure; CVD, cerebral vascular disease; DPP4I, dipeptidyl peptidase-4 inhibitors; F, female; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated hemoglobin; HDLC, high-density lipoprotein cholesterol; IHD, ischemic heart disease; M, male; SBP, systolic blood pressure; SGLT2I, sodium–glucose co-transporter 2 inhibitors; SU, sulfonylureas; TCH, total cholesterol; TG, triglycerides; TZD, thiazolidinedione.
Figure 3 | Adjusted hazard ratios for macroangiopathy in (a) younger and (b) elderly patients. The patients were divided into four groups by average glycated hemoglobin (HbA1c) value during the observation period based on the Kumamoto Declaration. Group K1, HbA1c < 6%; group K2, 6% ≤ HbA1c < 7%; group K3, 7% ≤ HbA1c < 8%; and group K4, HbA1c ≥ 8%. *P < 0.05 compared with group K2. †P < 0.01 compared with group K2.

Figure 4 | Adjusted hazard ratios for macroangiopathy in (a) younger and (b) elderly patients. The patients were divided into four groups by average glycated hemoglobin (HbA1c) value during the observation period based on the Japan Diabetes Society/Japan Geriatrics Society guidelines. Group E1, HbA1c < 7%; group E2, 7% ≤ HbA1c < 8%; group E3, 8% ≤ HbA1c < 8.5%; and group E4, HbA1c ≥ 8.5%. *P < 0.05 compared with group E1. †P < 0.01 compared with group E1.
These results are consistent with American Diabetes Association guidelines for older adults, which show that older adults who are healthy with few coexisting chronic illnesses and intact cognitive function and functional status should have lower glycemic goals (HbA1c 7.5%), whereas those with multiple coexisting chronic illnesses, cognitive impairment or functional dependence should have less stringent glycemic goals (HbA1c 8.0–8.5%) or IDF guidelines for older patients with type 2 diabetes, which suggest that glycemic control targets should be individualized taking into account functional status, comorbidities (especially the presence of established cerebral vascular disease), history and risk of hypoglycemia, and presence of microvascular complications.

Contrary to microangiopathy prevention, it was difficult to establish an HbA1c target for preventing macroangiopathy in elderly patients, because an average HbA1c threshold in elderly patients was not clear, despite the fact that a threshold of <7.0% had benefits in younger patients in both guidelines. Patients aged 45–69 years with type 2 diabetes in J-DOT3 showed benefits from strict control of maintaining average HbA1c at 6.8% in terms of the risk factors of nephropathy, retinopathy and cerebrovascular disease, compared with results obtained by maintaining HbA1c at 7.2%.

Considering the “legacy effect” from the UK Prospective Diabetes Study, the benefit of glycemic control in terms of macroangiopathy would be attenuated in elderly patients compared with younger patients. Also, in a previous cohort study designed to include patients aged 80 years and in which the mean age was 71 years with type 2 diabetes, mortality had a U-shaped relationship with HbA1c at baseline. In another study, Japanese Elderly Intervention Trial (J-EDIT), with Japanese type 2 diabetes patients aged >65 years suggested the existence of a J-shaped incidence for stroke according to HbA1c distribution at the landmark time-point, whereas the present study investigated the relationship between average HbA1c during observation and the onset of macroangiopathy. Because of the limited patient numbers and short observation period in the present study, it was difficult to investigate patients with lower and higher HbA1c to clarify the existence of a U or J shape, although the data from this study did suggest a faint U shape, in other words, a slight elevation in risks with an average HbA1c of <7% and that of >8.5%, as shown in Figure 4b. Other risks associated with macroangiopathy were adjusted only for BMI and medication(s) for hypertension and dyslipidemia, not for data on blood pressure and cholesterol levels.

Further study is required to clarify the optimal level of HbA1c for elderly diabetes patients. A recent systematic review showed that the paradigm of reducing blood glucose level as close as possible to normal (i.e., tight glycemic control of HbA1c <7%), independently of medication, when compared with conventional control (HbA1c 7.5–8.5%) did not have an impact on micro- and macrovascular outcomes, such as end-stage renal disease/dialysis, renal death, blindness, mortality, and cardiovascular endpoints, although the evidence is clear that chronic hyperglycemia is associated with an increased risk of adverse micro- and macrovascular outcomes. To consider subject characteristics, surrogate markers, and outcome, several studies therefore need to be compared and evaluated.

The present study had several limitations. First, it was a retrospective observational study with a limited study population. The observation period was also limited. It was therefore difficult to subdivide HbA1c levels into more detailed categories. Second, diabetes medication was not considered. Diabetes medication was chosen by the physician in charge based on a patient-centered approach considering the best available evidence in terms of benefits, harms, patient values, preferences and context in time, not only target HbA1c level. It was therefore difficult to discover the relationship between glycemic complications and HbA1c levels. Finally, we did not evaluate the habits and comorbid factors, such as smoking status, diet, cognitive function, frailty and daily activity. Because the aim of glycemic control for elderly patients with diabetes is not only prevention of complications but also maintaining quality of life, as well as prevention of geriatric syndrome, glycemic control only targeting HbA1c level is insufficient.

In conclusion, the glycemic control target for younger patients with type 2 diabetes should be <7.0% for average HbA1c to prevent micro- and macroangiopathy. On the contrary, the target for elderly patients with type 2 diabetes should be set individually to prevent macroangiopathy, and the target should be <7.0% to prevent microangiopathy.

DISCLOSURE
Hideaki Kaneto has received honoraria for lectures, and received scholarship grants from Sanofi, Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Taisho Toyama Pharma, MSD, Takeda, Ono Pharma, Daiichi Sankyo, Sumitomo Dainippon Pharma, Mitsubishi Tanabe Pharma, Kissei Pharma, Astellas, Novartis, Kowa, Chugai, Japan Foundation for Applied Enzymology and A2 Healthcare. Kohei Kaku has been an advisor to, received honoraria for lectures from, and received scholarship grants from Novo Nordisk Pharma, Sanwa Kagaku Kenkyusho, Takeda, Taisho Pharmaceutical Co., MSD, Taisho Toyama Pharma, Astellas, Kissei Pharma, Mitsubishi Tanabe Pharma Co., Ono Pharma Co., Sumitomo Dainippon Pharma, Novartis, Mitsubishi Tanabe Pharma, AstraZeneca, Nippon Boehringer Ingelheim Co., Fujifilm Pharma Co., and Sanofi. Masashi Shimoda and Shuhei Nakanishi have received honoraria for lectures from AstraZeneca and Sanofi, respectively. The other authors declare no conflict of interest.

REFERENCES
1. Araki E, Haneda M, Kasuga M, et al. New glycemic targets for patients with diabetes from the Japan Diabetes Society. J Diabetes Investig 2017; 8: 123–125.
2. Ueki K, Sasaki T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and...
mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. *Lancet Diabetes Endocrinol* 2017; 12: 951–964.

3. Japan Diabetes Society (JDS)/Japan Geriatrics Society (JGS) Joint Committee on Improving Care for Elderly Patients with Diabetes. Committee Report: glycemic targets for elderly patients with diabetes. *J Diabetes Investig* 2017; 8: 126–128.

4. Kimura T, Kaneto H, Kanda-Kimura Y, et al. Seven-year observational study on the association between glycemic control and the new onset of macroangiopathy in Japanese subjects with type 2 diabetes. *Intern Med* 2016; 55: 1419–1424.

5. Davis MD. Vitreous contraction in proliferative diabetic retinopathy. *Arch Ophthalmol* 1965; 74: 741–751.

6. Haneda M, Utsunomiya K, Koya D, et al. Classification of diabetic nephropathy 2014. *J Japan Diab Soc* 2014; 57: 529–534.

7. Yasuda H, Sanada M, Kitada K, et al. Rationale and usefulness of newly devised abbreviated diagnostic criteria and staging for diabetic polyneuropathy. *Diabetes Res Clin Pract* 2007; 77(Suppl 1): S178–S183.

8. American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2018. *Diabetes Care* 2018; 41(Suppl 1): S55–S64.

9. American Diabetes Association. 11. Older adults: standards of medical care in diabetes-2018. *Diabetes Care* 2018; 41(Suppl 1): S119–S125.

10. International Diabetes Federation. Global Guideline for Managing Older People with Type 2 Diabetes. Available from: https://www.idf.org/e-library/guidelines/78-global-guideline-for-managing-older-people-with-type-2-diabetes.html Accessed Mar 9, 2018.

11. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008; 359: 1577–1589.

12. Hamada S, Gulliford MC. Mortality in individuals aged 80 and older with type 2 diabetes mellitus in relation to glycosylated hemoglobin, blood pressure, and total cholesterol. *J Am Geriatr Soc* 2016; 64: 1425–1431.

13. Huang ES, Liu JY, Moffet HH, et al. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. *Diabetes Care* 2011; 34: 1329–1336.

14. Araki A, limuro S, Sakurai T, et al. Non-high-density lipoprotein cholesterol: an important predictor of stroke and diabetes-related mortality in Japanese elderly diabetic patients. *Geriatr Gerontol Int* 2012; 12(Suppl 1): 18–28.

15. Rodríguez-Gutiérrez R, Monfori VM. Glycemic control for patients with type 2 diabetes mellitus: our evolving faith in the face of evidence. *Circ Cardiovasc Qual Outcomes* 2016; 9: 504–512.

16. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998; 352: 837–853.

17. Zhang Y, Hu G, Yuan Z, et al. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. *PLoS ONE* 2012; 7: e42551.